Active substance Veliparib
Domain Oncology and Hematology
Reason of inclusion in Horizonscan Geneesmiddelen New medicine (specialité)
Main indication Breast cancer
Extended indication Breast cancer; HER2-negative metastatic or locally advanced unresectable BRCA-associated - first to third-line in combination with carboplatin and paclitaxel.


Manufacturer Abbvie
Mechanism of action PARP inhibitor
Route of administration Oral
Therapeutical formulation Capsule
Budgetting framework Intermural (MSZ)
Additional comments PARP-remmer


Registration route Centralised (EMA)
Submission date July 2020
Expected Registration August 2021
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Current treatment options Concurrentie van alle parp-remmers.
Therapeutic value No judgement
Duration of treatment Not found

Expected patient volume per year

Patient volume

< 189

Market share is generally not included unless otherwise stated.

References NKR
Additional comments NKR 2015: 1.885 mammacarcinomen HER- stadia 3 en 4. 5-10% van borstkankers wordt veroorzaakt door BRCA mutaties.

Expected cost per patient per year

Cost 30,000 - 60,000
Additional comments Afhankelijk van de behandelduur vergelijkbaar met olaparib en rucaparib. Inschatting €30.000-€60.000.

Potential total cost per year

Total cost


This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension No
References adisinsight
Additional comments Buiten de indicaties in de Horizonscan geen nieuwe indicatie-uitbreidingen.

Other information

There is currently no futher information available.